Associations between admission levels of multiple biomarkers and subsequent worse outcomes in acute ischemic stroke patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: United States NLM ID: 8112566 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-7016 (Electronic) Linking ISSN: 0271678X NLM ISO Abbreviation: J Cereb Blood Flow Metab Subsets: MEDLINE
    • Publication Information:
      Publication: 2016- : Thousand Oaks, CA : SAGE Publications
      Original Publication: New York : Raven Press, c1981-
    • Subject Terms:
      Biomarkers*/blood ; Ischemic Stroke*/blood; Humans ; Female ; Male ; Middle Aged ; Aged ; C-Reactive Protein/metabolism ; C-Reactive Protein/analysis ; Registries ; Interleukin-6/blood ; Chitinase-3-Like Protein 1/blood ; Prognosis ; Brain Ischemia/blood
    • Abstract:
      The modified Rankin Scale change score (ΔmRS) is useful for evaluating acute poststroke functional improvement or deterioration. We investigated the relationship between multiple biomarkers and ΔmRS by analyzing data on 6931 patients with acute ischemic stroke (average age 62.3 ± 11.3 years, 2174 (31.4%) female) enrolled from the Third China National Stroke Registry (CNSR-III) and 15 available biomarkers. Worse outcomes at 3 months were defined as ΔmRS 3m-discharge ≥1 (ΔmRS 3m-discharge  = mRS 3m -mRS discharge ). Adjusted odds ratios (aORs) and their 95% confidence intervals (CIs) were calculated from logistic regression models. At 3-months poststroke, 1026 (14.8%) patients experienced worse outcomes. The highest quartiles of white blood cells (WBCs) (aOR [95%CI],1.37 [1.12-1.66]), high-sensitivity C-reactive protein (hs-CRP) (1.37 [1.12-1.67]), interleukin-6 (IL-6) (1.43 [1.16-1.76]), interleukin-1 receptor antagonist (IL-1Ra) (1.46 [1.20-1.78]) and YKL-40 (1.31 [1.06-1.63]) were associated with an increased risk of worse outcomes at 3 months. Results remained stable except for YKL-40 when simultaneously adding multiple biomarkers to the basic traditional-risk-factor model. Similar results were observed at 6 and 12 months after stroke. This study indicated that WBCs, hs-CRP, IL-6, IL-1Ra, and YKL-40 were significantly associated with worse outcomes in acute ischemic stroke patients, and all inflammatory biomarkers except YKL-40 were independent predictors of worse outcomes at 3 months.
      Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
    • References:
      EBioMedicine. 2022 Jun;80:104054. (PMID: 35576642)
      Ann Neurol. 2023 Sep;94(3):572-584. (PMID: 37314250)
      Ann Neurol. 2010 Nov;68(5):672-80. (PMID: 21031582)
      Stroke. 2015 Aug;46(8):2238-43. (PMID: 26138130)
      Int J Stroke. 2022 Mar;17(3):260-268. (PMID: 33739214)
      Stroke Vasc Neurol. 2019 Jun 29;4(3):158-164. (PMID: 31709123)
      Stroke Vasc Neurol. 2020 Dec;5(4):337-347. (PMID: 33154178)
      Stroke. 2012 Jan;43(1):86-91. (PMID: 22020034)
      Stroke. 2017 Feb;48(2):327-334. (PMID: 28034963)
      Stroke. 1993 Jan;24(1):35-41. (PMID: 7678184)
      Acta Neuropathol. 2016 May;131(5):775-91. (PMID: 26860727)
      Acta Neurol Scand. 2017 Aug;136(2):97-102. (PMID: 27650381)
      J Neuroinflammation. 2022 Jun 6;19(1):131. (PMID: 35761288)
      BMC Neurol. 2004 Jan 15;4:2. (PMID: 14725719)
      Stroke. 2012 May;43(5):1266-72. (PMID: 22403046)
      J Stroke Cerebrovasc Dis. 2012 Nov;21(8):819-24. (PMID: 21703875)
      PLoS Med. 2009 Sep;6(9):e1000145. (PMID: 19901973)
      Stroke. 2009 Jul;40(7):2332-6. (PMID: 19461040)
      Adv Immunol. 1993;54:167-227. (PMID: 8379462)
      Neurocrit Care. 2011 Apr;14(2):244-52. (PMID: 21174170)
      Stroke. 2013 May;44(5):1232-7. (PMID: 23444308)
      Stroke. 2020 Nov;51(11):3215-3223. (PMID: 33054674)
      Immunobiology. 2012 May;217(5):483-91. (PMID: 21601307)
      Stroke. 2018 Oct;49(10):2430-2436. (PMID: 30355105)
      Nat Rev Neurol. 2016 Oct;12(10):594-604. (PMID: 27615422)
      Stroke. 2021 Jan;52(2):543-551. (PMID: 33430636)
      Mayo Clin Proc. 2020 May;95(5):955-965. (PMID: 32370856)
      Stroke. 2016 Aug;47(8):2025-30. (PMID: 27328699)
      PLoS One. 2012;7(12):e51722. (PMID: 23272150)
      Acta Pharmacol Sin. 2018 Jul;39(7):1228-1236. (PMID: 29926842)
      Atherosclerosis. 2017 Nov;266:1-7. (PMID: 28934604)
      Stroke. 2021 Aug;52(9):3013-3024. (PMID: 34399587)
      Annu Rev Physiol. 2011;73:479-501. (PMID: 21054166)
      Circ Res. 2019 Jan 4;124(1):18-20. (PMID: 30605410)
      Int J Mol Sci. 2020 Sep 04;21(18):. (PMID: 32899616)
      Int J Stroke. 2009 Jun;4(3):200-5. (PMID: 19659822)
      J Neurol. 2009 Dec;256(12):2003-8. (PMID: 19609738)
      Eur J Neurol. 2014 Feb;21(2):215-22. (PMID: 23848934)
      Transl Stroke Res. 2022 Apr;13(2):228-237. (PMID: 34165728)
      Crit Rev Clin Lab Sci. 2016 Dec;53(6):396-408. (PMID: 27187575)
      Stroke. 2021 Jan;52(1):132-141. (PMID: 33317415)
    • Contributed Indexing:
      Keywords: Blood biomarkers; acute ischemic stroke; inflammation; modified Rankin Scale; worse outcomes
    • Accession Number:
      0 (Biomarkers)
      9007-41-4 (C-Reactive Protein)
      0 (Interleukin-6)
      0 (Chitinase-3-Like Protein 1)
    • Publication Date:
      Date Created: 20231117 Date Completed: 20240425 Latest Revision: 20240627
    • Publication Date:
      20240627
    • Accession Number:
      PMC11197142
    • Accession Number:
      10.1177/0271678X231214831
    • Accession Number:
      37975323